Clinical reference Biomarker Directory
Back to directory

Biotinidase

Established

Biotinidase is an enzyme whose deficiency is detected via newborn screening and treated with biotin supplements.

Also known as BTD enzyme
In plain language

This enzyme helps the body reuse vitamin B7. Babies missing enough of it can develop serious problems, but a simple newborn heel-prick blood test catches it early, and treatment is as simple as a daily vitamin supplement.

Biomarker & context

Biotinidase is an enzyme that recycles biotin (vitamin B7) from proteins for reuse by the body. Deficiency causes an inherited metabolic disorder that impairs energy metabolism and, if untreated, leads to serious neurological damage.

What it indicates

Low biotinidase enzyme activity on newborn screening indicates biotinidase deficiency, which exists in profound (severe) and partial forms; early identification allows biotin supplementation before symptoms (seizures, hearing loss, developmental delay) develop.

Diagnosis & clinical testing

Screened via dried blood spot at birth measuring enzyme activity; confirmatory testing includes repeat blood biotinidase activity and BTD gene sequencing. Prenatal testing is available via chorionic villus sampling or amniocentesis in at-risk pregnancies.

Guiding treatment

Profound deficiency is treated with lifelong oral biotin supplementation, typically preventing all symptoms if started before onset; partial deficiency management (dosing, duration) remains an area of ongoing clinical debate.

Clinical significance

Standard component of newborn screening panels; excellent prognosis when treated before symptom onset.

References
  1. NORD. (2023). Biotinidase Deficiency.
  2. Regional Centre for Newborn Screening of Verona. (2021). Newborn Screening for Biotinidase Deficiency: The Experience of a Regional Center in Italy. PMC.